MROSS, Klaus et al. Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancer. Vascular Cell, [S.l.], v. 3, n. 1, p. 16, july 2011. ISSN 2045-824X. Available at: <https://vascularcell.com/index.php/vc/article/view/10.1186-2045-824X-3-16>. Date accessed: 14 nov. 2024. doi: http://dx.doi.org/10.1186/2045-824X-3-16.